Vitamin D occupies a peculiar position in the sports nutrition landscape. Once dismissed as merely the bone health vitamin, it has emerged as a legitimate performance-modulating hormone influencing skeletal muscle function, mitochondrial efficiency, calcium handling, and immune surveillance. The Vitamin D Receptor (VDR) is expressed in virtually every tissue relevant to athletic output.

Yet the enthusiasm surrounding vitamin D supplementation has outpaced the nuance of the evidence. The narrative has drifted from correcting frank deficiency to pursuing supraphysiological serum concentrations under the assumption that if some is beneficial, more must be superior. This is a fundamental misreading of the dose-response curve.

The relationship between serum 25-hydroxyvitamin D and performance is not linear. It follows a threshold-plateau pattern, with clear diminishing returns and, at sufficiently elevated concentrations, evidence of hypercalcemic risk, soft tissue calcification, and paradoxical immune dysregulation. Understanding where correction ends and excess begins is the difference between an evidence-based protocol and speculative megadosing. This article defines that threshold and outlines a testing and supplementation strategy grounded in exercise biochemistry rather than internet folklore.

Serum 25(OH)D concentrations below 30 ng/mL (75 nmol/L) are consistently associated with measurable decrements in athletic capacity. The mechanisms are well characterized: reduced type II muscle fiber cross-sectional area, impaired sarcoplasmic reticulum calcium reuptake, and downregulated mitochondrial oxidative phosphorylation.

Close et al. demonstrated that athletes with baseline 25(OH)D under 30 ng/mL showed significant improvements in 10-meter sprint times and vertical jump after correction, with no further gains once levels exceeded 50 ng/mL. Owens and colleagues extended this by documenting VDR-mediated changes in myogenic differentiation, offering a mechanistic basis for the observed strength deficits.

The immunological dimension is equally consequential for training availability. Insufficient vitamin D status compromises antimicrobial peptide expression, particularly cathelicidin, elevating upper respiratory tract infection incidence during heavy training blocks. He et al. reported that athletes with 25(OH)D below 30 ng/mL sustained substantially more URTI symptom-days across a competitive season.

Injury susceptibility follows a similar pattern. Stress fracture incidence, muscle strain rates, and prolonged recovery from soft tissue injury all correlate inversely with serum vitamin D within the insufficiency range. This is not speculative; military cohort data provide some of the cleanest evidence linking suboptimal status to skeletal injury.

The practical implication is that identifying and correcting deficiency yields disproportionate performance dividends. The largest gains occur when moving athletes from deficient to sufficient, not from sufficient to elevated.

Takeaway

Biological systems respond most dramatically to the correction of deficits, not the amplification of adequacy. The steepest gains live at the bottom of the curve.

The evidence converges on a target serum 25(OH)D range of 40 to 60 ng/mL (100 to 150 nmol/L) for performance-oriented individuals. Below 40 ng/mL, incremental improvements in neuromuscular function, VO2max, and immune competence remain measurable. Above 60 ng/mL, the performance curve flattens definitively.

This ceiling is not arbitrary. Dahlquist and colleagues, in their review of vitamin D and athletic performance, identified 40 ng/mL as the practical minimum for optimization and cautioned against pursuing concentrations exceeding 80 ng/mL absent specific clinical rationale. Beyond this point, the risk profile begins to shift unfavorably.

Supraphysiological levels above 100 ng/mL introduce concerns that are frequently ignored in athletic circles. Hypercalcemia, hypercalciuria, and vascular calcification represent genuine hazards, particularly when high-dose supplementation is combined with calcium co-ingestion. There is also emerging evidence of U-shaped immune responses, where excessive vitamin D may impair certain aspects of T-cell function.

The threshold-plateau model has ergogenic implications. Once an athlete reaches the 40 to 60 ng/mL window, additional supplementation is essentially wasted intervention. Resources are better redirected toward other modifiable variables: iron status, omega-3 index, or magnesium sufficiency, all of which often show greater room for optimization.

Seasonal fluctuation must also be factored. Endogenous synthesis varies markedly with latitude, training environment, and skin pigmentation. Indoor and winter athletes at higher latitudes may drop 15 to 20 ng/mL between summer peak and late winter trough, necessitating adjusted dosing schedules.

Takeaway

Optimization is not maximization. Every physiological parameter has a window of function beyond which further intervention produces indifference, then harm.

Any competent vitamin D protocol begins with serum 25(OH)D testing, not standardized dosing. Baseline status determines corrective load, and without measurement, supplementation is guesswork. Test twice annually at minimum: late summer to establish peak endogenous production and late winter to identify trough exposure.

For athletes presenting below 20 ng/mL, a loading protocol of 5,000 to 10,000 IU cholecalciferol daily for 8 to 12 weeks, followed by retesting, is well supported. Those in the 20 to 30 ng/mL range typically respond to 4,000 to 5,000 IU daily. Athletes already within 30 to 40 ng/mL may require only 1,000 to 2,000 IU daily as maintenance.

Cholecalciferol (D3) is unequivocally preferred over ergocalciferol (D2) based on superior serum-raising efficacy. Co-ingestion with dietary fat is non-negotiable given its lipophilic absorption profile. Vitamin K2 (menaquinone-7) at 100 to 200 mcg may be prudent alongside higher doses to direct calcium metabolism toward bone rather than vasculature.

Monitoring must include not only 25(OH)D but also serum calcium and, at higher supplementation loads, parathyroid hormone. Elevated calcium with suppressed PTH signals excess. This is the biochemical fingerprint that should terminate escalation regardless of the 25(OH)D number.

Individual variation in vitamin D binding protein polymorphisms and VDR sensitivity means identical serum concentrations produce different bioactive effects across athletes. Response, not dose, is the outcome measure that matters.

Takeaway

Test, treat, retest, adjust. A protocol without measurement is a preference dressed in scientific language.

Vitamin D exemplifies the broader principle that dominates advanced sports nutrition: benefit follows a curve, not a line. Correcting insufficiency produces meaningful performance gains across muscular, immunological, and skeletal domains. Pushing beyond sufficiency produces nothing but expense and, eventually, risk.

The 40 to 60 ng/mL window represents current best evidence for the intersection of performance benefit and physiological safety. This target should be pursued through measured supplementation, seasonal adjustment, and periodic testing rather than empirical megadosing driven by anecdote.

The athletes who extract the most from vitamin D are not those consuming the highest doses but those who identify their baseline, correct any deficit efficiently, and then redirect attention to the next limiting variable. Precision replaces enthusiasm, and results follow.